Last reviewed · How we verify

Cephalon, Inc. — Portfolio Competitive Intelligence Brief

Cephalon, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Liposomal doxorubicin hydrochloride Liposomal doxorubicin hydrochloride marketed Antineoplastic agent DNA and topoisomerase II Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Acrotech Biopharma Inc. · 1 shared drug class
  2. Asan Medical Center · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Beijing Biostar Pharmaceuticals Co., Ltd. · 1 shared drug class
  5. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 shared drug class
  6. Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 shared drug class
  7. Sanofi · 1 shared drug class
  8. Seattle Project Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cephalon, Inc.:

Cite this brief

Drug Landscape (2026). Cephalon, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cephalon-inc. Accessed 2026-05-16.

Related